Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 19/20 | 0.62 |
| ▸ | PYGL | P06737 | 18/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30157261 | 1.00 | PYGM (0.62) | PYGMPYGLALOX15 | |
| SCHEMBL9865950 | 0.91 | PYGM (0.52) | PYGMPYGL | |
| SCHEMBL9864934 | 0.90 | PYGM (0.49) | PYGMPYGL | |
| SCHEMBL9865516 | 0.89 | PYGL (0.48) | PYGMPYGL | |
| SCHEMBL9867642 | 0.87 | PYGL (0.46) | PYGMPYGL | |
| SCHEMBL9865794 | 0.86 | PYGM (0.46) | PYGMPYGL | |
| SCHEMBL10425160 | 0.86 | PYGM (0.46) | PYGMPYGLALOX15 | |
| SCHEMBL9829022 | 0.86 | PYGL (0.48) | PYGMPYGLALOX15 | |
| SCHEMBL10659301 | 0.86 | PYGL (0.52) | PYGMPYGL | |
| SCHEMBL9865957 | 0.84 | PYGL (0.44) | PYGMPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| US-5026714-A | Novel 1-alkyl-substituted 1,4-dihydropyridinelactone anti-diabetics | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-25 | — | — | US | claimed |
| EP-0158138-B1 | 1-ALKYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE LACTONES, METHOD FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1988-10-12 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
| WO-2009048746-A2 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | ELC MANAGEMENT LLC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | ELC MANAGEMENT LLC | 2009-04-09 | — | — | US | disclosed |
| US-4786641-A | HYPOGLYCEMIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PYGM 1715/4885PYGL 1869/4885ALOX15 453/4885 |
| US-20090092566-A1 | SELF-TANNING COSMETIC COMPOSITIONS AND METHODS | TNNI3K, CHEK1, CHEK2 | PYGM 1576/4885PYGL 3074/4885ALOX15 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.